Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alfa (PRX-102) in Patients With Fabry Disease
Latest Information Update: 27 May 2025
At a glance
- Drugs Pegunigalsidase alfa (Primary)
- Indications Fabry's disease
- Focus Adverse reactions; Registrational
- Sponsors Chiesi; Protalix Biotherapeutics
Most Recent Events
- 20 May 2025 Status changed from active, no longer recruiting to completed.
- 19 Dec 2024 Planned End Date changed from 30 Apr 2025 to 28 Mar 2026.
- 19 Dec 2024 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.